Liver Lineup: Managing MASLD and MASH Amid Limited Awareness, Overlapping Risk Factors

About this episode

The episode discusses the challenges and advancements in managing MASLD and MASH in hepatology.

In this episode of Liver Lineup: Updates and Unfiltered Insights , Nancy Reau, MD, and Kimberly Brown, MD, turn their attention to metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH), conditions that now dominate hepatology clinics but continue to pose major diagnostic and therapeutic challenges. As new drugs enter the clinic and others advance through the pipeline, the hosts explore what meaningful progress looks like in a disease space defined by heterogeneity, comorbidities, and ongoing uncertainty around long-term outcomes. Key episode timestamps: 0:00:00 – Intro + global MASLD burden and mortality; who progresses to severe liver disease. 0:03:00 – Very low disease awareness; advanced MASLD often missed. 0:06:32 – Weak FIB‑4–based referral patterns; need automated pathways. 0:10:54 – Alcohol underreporting; role of PEth in honest discussions. 0:15:18 – “Modest” alcohol still harmful in MASLD; no truly safe level. 0:19:40 – Semaglutide/GLP‑1 benefits on liver outcomes beyond weight loss. 0:23:22 – FGF‑21 agents improving portal hypertension in advanced disease. 0:24:03 – Carvedilol less effective for…

People in this episode

Hosts: Nancy Reau, Kimberly Brown

Topics covered

• metabolic dysfunction–associated steatotic liver disease
• metabolic dysfunction–associated steatohepatitis
• hepatology
• diagnostic challenges
• therapeutic challenges
• drug development
• comorbidities
• long-term outcomes

Keywords

• MASLD
• MASH
• liver disease
• FIB-4
• PEth
• semaglutide
• FGF-21
• carvedilol

Mentioned in this episode

Products: semaglutide, FGF-21, carvedilol

Books & works: Liver Lineup: Updates and Unfiltered Insights

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min